Greengo
1 month ago
As a PetVivo salesman, I’d like to discuss why Spryng is a superior choice for treating osteoarthritis in dogs and cats compared to Librela. Let’s examine the facts: Librela’s Concerning Safety Profile Librela, while marketed as an effective treatment, comes with significant risks: • The FDA received over 3,800 reports of side effects through the end of 2023 • The European Medicines Agency received more than 12,300 adverse event reports since 2021 These side effects include: • Ataxia • Seizures • Neurological issues (paresis, recumbency) • Urinary incontinence • Polyuria and polydipsia • In some cases, death or euthanasia Just three weeks ago, the FDA cited Zoetis for potentially underreporting more severe side effects, raising serious concerns about the drug’s safety profile. Problems with Nerve Growth Factor Inhibition Librela’s mechanism of action, inhibiting nerve growth factor (NGF), can lead to: • Increased risk of rapidly progressive osteoarthritis • Potential for osteonecrosis • Systemic effects throughout the body, not just in affected joints • Dramatic increase in systemic oxidative stress, particularly harmful for animals in pre-arthritis and early arthritis stages Spryng: A Superior Alternative Now, let me introduce you to Spryng, a revolutionary treatment that addresses the root cause of osteoarthritis: 1. Mechanism of Action: • Provides a shock-absorbing matrix that mimics natural cartilage • Directly addresses joint mechanics, not just masking pain 2. Safety Profile: • Demonstrated excellent safety in clinical studies • No significant adverse events reported • Localized to the injected joint, minimizing systemic effects 3. Long-lasting Effects: • A single injection can provide benefits for up to 12 months or longer • Compared to Librela’s required monthly injections 4. Cost-effective: • Approximately 50% cheaper for the customer over the course of a year 5. Natural Composition: • Made from purified, naturally-derived proteins and carbohydrates • Mimics the structure and function of natural cartilage 6. Regulatory Advantage: • Classified as a veterinary medical device, not requiring FDA premarket approval 7. Versatility: • Effective for all stages of osteoarthritis • Can be used in multiple joint locations By choosing Spryng, you’re offering your patients a safer, more effective, and cost-efficient solution for managing osteoarthritis. It’s time to move beyond simply masking pain and address the underlying cause of joint issues, providing long-term relief and improved quality of life for our furry companions.
Greengo
1 month ago
Investment Pitch: PetVivo Holdings (PETV) - A Promising Opportunity in the Canine Arthritis
Treatment Market Market Overview The canine arthritis treatment market is experiencing
significant growth, with Zoetis Inc. (ZTS) leading the way with its Librela product. However,
recent developments have created an opportunity for PetVivo Holdings (PETV) to capture
market share with its innovative Spryng
™
treatment. Zoetis’s Librela: Market Leader Facing
Challenges Librela, Zoetis’s flagship product for canine osteoarthritis, has achieved
remarkable success:
• $400 million in global canine market sales for 2024 • 90% contribution margins, adding
$360 million to ZTS earnings (approximately 15%)
• Monthly injection priced at $160 retail However, Librela is now facing significant
headwinds: • FDA warning issued to veterinarians about serious adverse events in dogs
treated with Librela • Reported side effects include ataxia, seizures, impaired muscle
function, and in some cases, death
• This FDA response typically causes hesitation among veterinarians in prescribing the
medication PetVivo’s Spryng
™
: A Promising Alternative PetVivo’s Spryng
™ with
OsteoCushion
™
Technology offers several advantages: • Once-per-year injection priced at
$600, potentially more cost-effective for pet owners
• FDA
-approved veterinary medical device, not a drug, offering pain moderation without
pharmacologic action
• No reported serious side effects
• Natural, viscosolid matrices that mimic cartilage properties • Long-lasting joint benefits
from a single treatment
• Can be used in multiple joints as part of the same treatment Market Opportunity for
PetVivo
1. Established Distribution: MWI, a division of AmerisourceBergen, the largest drug
distributor, markets PetVivo’s Spryng product
2. Market Reach: PetVivo has reached all small animal vets over the past 2 years,
positioning it to capitalize on Librela’s challenges
3. Competitive Advantage: Spryng is the only naturally derived cartilage reinforcement
product for veterinary use
4. Growth Potential: With Zoetis facing regulatory challenges, PetVivo is well-positioned to
capture market share
5. Valuation Disparity: • Zoetis: $73 billion market cap • PetVivo: $12 million market cap
Investment Thesis 3. Untapped Potential: PetVivo’s small market cap compared to Zoetis
suggests significant room for growth 2. Product Superiority: Spryng’s natural composition
and less frequent dosing may appeal to pet owners and veterinarians concerned about
Librela’s side effects 3. Market Disruption Opportunity: FDA warnings about Librela create
an opening for alternative treatments like Spryng 4. Established Infrastructure: PetVivo’s
existing relationships with veterinarians and partnership with a major distributor provide a
solid foundation for rapid market penetration 5. Regulatory Advantage: As a medical
device, Spryng may face less scrutiny than drug-based treatments Risks to Consider •
Competition from other major players like Merck Animal Health • Potential for Zoetis to
address FDA concerns and maintain market dominance • Execution risks associated with
scaling up production and sales Conclusion PetVivo Holdings (PETV) represents a
compelling investment opportunity in the canine arthritis treatment market. With its
innovative Spryng
™
product, established distribution channels, and the current challenges
facing the market leader, PetVivo is well-positioned to capture significant market share and
potentially deliver substantial returns to investors.
tw0122
3 years ago
Time to vaccinate your cats and dogs for Covid-19.
Zoetis creator of Covid-19 Vaccine for animals.
The Detroit Zoo in Michigan has launched a drive to vaccinate its animals against Covid-19, using a specially designed shot to immunize gorillas, lions, chimpanzees and other critters thought to be most susceptible to the virus.
Joining more than 5 million fully vaccinated Michiganders – humans, that is – some animals at the Detroit Zoo are now being inoculated with a special vaccine created for veterinary use, the Detroit Zoological Society (DZS) announced in a statement on Monday.
“Much like we vaccinate dogs for things like parvovirus, distemper or rabies, this is needed to protect animals at the Zoo,” said Dr. Ann Duncan, director of animal health for the DZS.
Detroit Zoo's most susceptible animals are getting COVID-19 vaccinations
Detroit Zoo's most susceptible animals are getting COVID-19 vaccinations
freep.com
Developed by Zoetis – a pharma firm whose research team is based in Kalamazoo, Michigan – the animal-specific vaccine was first administered to gorillas, chimpanzees, tigers and lions at the Detroit facility. While the zoo said none of its animals have yet contracted the illness, it noted that cases have been detected at other American zoos, and that a tiger and a lion had died from the virus at facilities in India and Europe, suggesting risk of infection does exist for many animals.
“We’re both thankful and relieved a special vaccine is now available to protect against Covid-19,” Scott Carter, chief life sciences officer for the zoological society, added.
Many of the mammals are trained to present themselves to our animal care staff for minor medical procedures, including vaccinations.
Eight lions contract Covid-19 at Hyderabad zoo amid coronavirus surge in India
The Zoetis jab was first unveiled earlier this year at a zoo in San Diego, California, where four orangutans and five bonobos became the first non-human primates to be vaccinated against the virus. Eight gorillas at the same zoo had previously tested positive for the virus – reportedly the first of their species to do so – but were not vaccinated as they were thought to have developed natural immunity.
Though the company originally developed the formulation for dogs and cats, it appears to have worked as intended in other animals and has triggered no adverse reactions.
Zoetis is not the only pharma firm looking to produce jabs for other creatures, however, with the Russian-developed Carnivac-Cov vaccine officially registered by the country’s regulators last March. Touted by its creators as “the first, and to date, the only Covid-19 product in the world for animals,” the vaccine was proven effective for dogs, cats, arctic foxes and minks, among others.
stocktrademan
10 years ago
$ZTS DD Notes ~ http://www.ddnotesmaker.com/ZTS
bullish
$ZTS recent news/filings
## source: finance.yahoo.com
Wed, 17 Dec 2014 22:55:48 GMT ~ Zoetis Boosts Dividend After Ackman Raises Stake
read full: http://www.bloomberg.com/news/2014-12-17/zoetis-boosts-dividend-after-ackman-raises-stake.html?cmpid=yhoo
*********************************************************
Wed, 17 Dec 2014 21:27:41 GMT ~ Zoetis raises quarterly dividend 15%
read full: http://www.marketwatch.com/News/Story/Story.aspx?guid=6BFBC7A0-916C-4240-9167-07001708F373&siteid=yhoof2
*********************************************************
Wed, 17 Dec 2014 21:18:50 GMT ~ ZOETIS INC. Files SEC form 8-K, Regulation FD Disclosure
read full: http://biz.yahoo.com/e/141217/zts8-k.html
*********************************************************
Wed, 17 Dec 2014 21:15:00 GMT ~ Zoetis Declares First Quarter 2015 Dividend; Board Approves 15% Payment Increase
[Business Wire] - The Board of Directors of Zoetis Inc. has declared a first quarter 2015 dividend payable to holders of the company’s common stock of $0.083 per share, an increase of 15% from the quarterly dividend rate paid in 2014.
read full: http://finance.yahoo.com/news/zoetis-declares-first-quarter-2015-211500638.html
*********************************************************
Wed, 17 Dec 2014 13:29:00 GMT ~ Zoetis to Participate in the 33rd Annual J.P. Morgan Healthcare Conference
[Business Wire] - Zoetis Inc. will participate in the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts.
read full: http://finance.yahoo.com/news/zoetis-participate-33rd-annual-j-132900016.html
*********************************************************
$ZTS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ZTS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ZTS/company-info
Ticker: $ZTS
OTC Market Place: Not Available
CIK code: not found
Company name: Zoetis Inc.
Incorporated In:
$ZTS share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$ZTS extra dd links
Company name: Zoetis Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ZTS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ZTS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ZTS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/news - http://finance.yahoo.com/q/h?s=ZTS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ZTS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ZTS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ZTS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Zoetis+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Zoetis+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Zoetis+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ZTS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ZTS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ZTS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ZTS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ZTS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ZTS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ZTS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ZTS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ZTS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ZTS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ZTS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ZTS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ZTS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ZTS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ZTS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ZTS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ZTS
$ZTS DD Notes ~ http://www.ddnotesmaker.com/ZTS
stocktrademan
10 years ago
$ZTS DD Notes ~ http://www.ddnotesmaker.com/ZTS
bullish
$ZTS recent news/filings
## source: finance.yahoo.com
Wed, 03 Dec 2014 16:32:01 GMT ~ Zoetis in a Growing Global Animal Health Industry
read full: http://finance.yahoo.com/news/zoetis-growing-global-animal-health-163201790.html
*********************************************************
Tue, 02 Dec 2014 13:29:00 GMT ~ Zoetis to Participate in the Bank of America Animal & Dental Health Summit
[Business Wire] - Zoetis Inc. will participate in the Bank of America Animal & Dental Health Summit on Thursday, Dec. 11, in Boston, Mass. Paul Herendeen, Executive Vice President and Chief Financial Officer, and Clint Lewis, Executive Vice President and President, U.S.
read full: http://finance.yahoo.com/news/zoetis-participate-bank-america-animal-132900049.html
*********************************************************
Wed, 26 Nov 2014 14:03:43 GMT ~ Jefferies Raises Zoetis Price Target, Says Consolidation Continues To Look Likely
read full: http://finance.yahoo.com/news/jefferies-raises-zoetis-price-target-140343487.html
*********************************************************
Mon, 24 Nov 2014 23:29:04 GMT ~ Bayer explores possible sale of diabetes device unit -Bloomberg
read full: http://uk.finance.yahoo.com/news/bayer-explores-possible-sale-diabetes-232904416.html
*********************************************************
Mon, 24 Nov 2014 14:00:00 GMT ~ Zoetis Announces Appointment of Roman Trawicki as President of Global Manufacturing and Supply
[Business Wire] - Zoetis Inc. today announced the appointment of Roman Trawicki as President of its Global Manufacturing and Supply organization.
read full: http://finance.yahoo.com/news/zoetis-announces-appointment-roman-trawicki-140000089.html
*********************************************************
$ZTS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ZTS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ZTS/company-info
Ticker: $ZTS
OTC Market Place: Not Available
CIK code: not found
Company name: Zoetis Inc.
Incorporated In:
$ZTS share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$ZTS extra dd links
Company name: Zoetis Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ZTS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ZTS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ZTS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/news - http://finance.yahoo.com/q/h?s=ZTS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ZTS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ZTS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ZTS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Zoetis+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Zoetis+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Zoetis+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ZTS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ZTS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ZTS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ZTS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ZTS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ZTS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ZTS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ZTS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ZTS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ZTS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ZTS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ZTS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ZTS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ZTS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ZTS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ZTS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ZTS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ZTS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ZTS
$ZTS DD Notes ~ http://www.ddnotesmaker.com/ZTS
DanClark69
11 years ago
ZTS Zoetis Inc, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The primary livestock species are cattle (both beef and dairy), swine, poultry, sheep and fish, and the primary companion animal species are dogs, cats and horses. The Company’s more than 300 product lines include vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceutical products. The Company’s product portfolio also includes businesses, such as diagnostics, genetics, devices and services, such as dairy data management, e-learning and professional consulting. The Company operates in North America, Europe, Africa, Asia, Australia and Latin America.
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
fung_derf
3 weeks ago
BottomBounce
5 years ago
ValueInvestor15
8 years ago
DewDiligence
10 years ago
beachcomber1
10 years ago
